



03 March 2009

ASX Announcement

## **BIONOMICS LIMITED BROADCAST**

**BIONOMICS LIMITED (BNO)** provides the opportunity to listen to an audio broadcast with **Dr Deborah Rathjen, CEO and MD** in a presentation titled “**BNO – Half Yearly Report and Accounts – Dr Deborah Rathjen, CEO & MD.**”

*To listen, simply click on the link below:*

<http://www.brr.com.au/event/55851>

The presentation details are as follows:

- ***BNO Half Yearly Report***
- ***Outlook***

**Boardroomradio offers many free services, such as:**

- [Boardroomradio Alerts](#)
- Easy access to archived presentations on demand
- Podcast subscription with daily updates

Visit <http://www.brr.com.au> for more

**For further information:**

**DR DEBORAH RATHJEN  
CEO & MANAGING DIRECTOR  
BIONOMICS LIMITED  
Ph: +61 8 8354 6101**

### **About Bionomics Limited**

Bionomics (ASX: BNO) discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. Bionomics' most advanced program, BNC105, BNC210, for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, the company's angiogenesis target and drug discovery platform, incorporates a variety of genomics tools to identify and validate novel angiogenesis targets. MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs

targeting ion channels for diseases of the central nervous system. For more information about Bionomics, visit [www.bionomics.com.au](http://www.bionomics.com.au)

### **Factors Affecting Future Performance**

*This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments, including, without limitation, statements made regarding BNC105, BNC210, BNO69 and its' drug development programs are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward looking statements, including risks related to our available funds or existing funding arrangements, a further downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.*